Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

553 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-06

Study Completion Date

2023-08-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heart failure with preserved ejection and hypertrophic cardiomyopathy are common diseases and often associated with transthyretin cardiac amyloidosis (TTR-CM), especially in elderly people. Nevertheless, research of TTR-CM is recommended in patients with ventricular hypertrophy without other cause such as valvular disease or hypertension. Therefore, the exact prevalence of TTR-CM remains unknown. We aim to determine the prevalence of TTR-CM in patients with ventricular hypertrophy and aged ≥ 60 years old, hospitalized in our cardiology department (CHU de Poitiers) by performing bone scintigraphy and research of AL amyloidosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transthyretin Cardiac Amyloidosis in HFpEF

NCT03414632

Heart Failure With Preserved Ejection Fraction

COMPLETED EARLY_PHASE1

High Resolution Three-dimensional Maps of the Right Chambers in Patient Diagnosed With Cardiac Amyloidosis

NCT04956965

Cardiac Amyloidosis Cardiac Disease

UNKNOWN NA

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

NCT04899180

Aortic Stenosis Transthyretin Amyloidosis Transthyretin Amyloid Cardiomyopathy +1 more

COMPLETED EARLY_PHASE1

Early Detection of Cardiac Amyloidosis

NCT05010980

Amyloidosis Aortic Valve Stenosis

UNKNOWN

Amyloidosis TTR Flow Reserve Evaluation

NCT05103943

Amyloid Cardiomyopathy

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Not Provided

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transthyretin Cardiac Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bony scintigraphy

Bony scintigraphy within 1 to 4 months after inclusion

Group Type EXPERIMENTAL

Bony scintigraphy

Intervention Type PROCEDURE

Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bony scintigraphy

Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient ≥ 60 years, hospitalised in cardiology wards of the Centre Hospitalier Universitaire of Poitiers
* Left ventricle hypertrophy on echocardiography
* Patient able to comply with study procedures
* Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures
* Patient having signed an informed consent after clear and fair information on the study

Exclusion Criteria

* CardiacTransplant
* Complex congenital cardiopathies
* Know diagnosis of amylosis
* Contra-indication to bony scintigraphy : hypersensitivity to sodium oxidronate or one of its excipients, or to one of the components of radiopharmaceutic marked product ;
* Subject not able to comply with study procedures
* Patients not benefiting from a Social Security scheme or not benefiting from it through a third party
* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, patients staying in a health or social establishment, adults under legal protection, and patients in emergency situation.
* Women not menopausal

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No